Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5970532 | 0.90 | MEN1 (0.50) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL3835248 | 0.85 | MEN1 (0.51) | ALDH1A1GPR35MEN1HTTKMT2A | |
| SCHEMBL525661 | 0.85 | PDGFRB (0.47) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL30098373 | 0.84 | GPR35 (0.56) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL591200 | 0.84 | GPR35 (0.56) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL24723054 | 0.83 | PDGFRB (0.45) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL4196549 | 0.83 | ALDH1A1 (0.45) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL22081952 | 0.83 | RORC (0.46) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL4195883 | 0.83 | ALDH1A1 (0.46) | ALDH1A1GPR35PDGFRBFGFR1PDGFRA | |
| SCHEMBL5924264 | 0.83 | GPR35 (0.54) | ALDH1A1GPR35MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1944290-B1 | NOVEL 1-2-DIHYDROQUINOLINE DERIVATIVE HAVING GLUCOCORTICOID RECEPTOR BINDING ACTIVITY | SANTEN PHARMACEUTICAL CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-8420635-B2 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| CN-102311385-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2012-01-11 | — | — | CN | disclosed |
| CN-102304124-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2012-01-04 | — | — | CN | disclosed |
| CN-102229562-A | Novel 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity | SANTEN PHARMACEUTICAL CO LTD | 2011-11-02 | — | — | CN | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-4159384-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4123455-A | COMPLEMENT INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1978-10-31 | — | — | US | disclosed |
| US-4060637-A | 5-BROMO-N-(N,N'-DIALKYLAMINOALKYL)-O-CRESOTAMIDES | PIERRE FABRE SA (FR) | 1977-11-29 | — | — | US | disclosed |
| US-3958002-A | ADMINISTERING | PIERRE FABRE S.A. (FR) | 1976-05-18 | — | — | US | disclosed |
| US-3941878-A | ASPIRIN, A CRESOTAMIDE | PIERRE FABRE S.A. (FR) | 1976-03-02 | — | — | US | disclosed |
| US-3940490-A | N-ALKYL-5-BROMO-ORTHO-CRESOTAMIDES, ANTICONVULSANT | PIERRE FABRE S.A. (FR) | 1976-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | ALDH1A1 1918/4885GPR35 2535/4885PDGFRB 232/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | ALDH1A1 1987/4885GPR35 2475/4885PDGFRB 232/4885 |
| US-20110263589-A1 | Method for preventing or treating a glucocorticoid receptor-related disease | NR3C1, NR3C2, NR5A1 | ALDH1A1 3037/4885GPR35 622/4885PDGFRB 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.